<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Nasiri Sovari, Sara</dc:creator>
  <dc:creator>Kolly, Isabelle</dc:creator>
  <dc:creator>Schindler, Kevin</dc:creator>
  <dc:creator>Djuric, Ana</dc:creator>
  <dc:creator>Srdic-Rajic, Tatjana</dc:creator>
  <dc:creator>Crochet, Aurélien</dc:creator>
  <dc:creator>Pavic, Aleksandar</dc:creator>
  <dc:creator>Zobi, Fabio</dc:creator>
  <dc:date>2023</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">We report the synthesis, characterization, and in vivo evaluation of the anticancer activity of a series of 5- and 6-(halomethyl)-2,2′-bipyridine rhenium tricarbonyl complexes. The study was promoted in order to understand if the presence and position of a reactive halomethyl substituent on the diimine ligand system of fac-[Re(CO)3]+ species may be a key molecular feature for the design of active and non-toxic anticancer agents. Only compounds potentially able to undergo ligand-based alkylating reactions show significant antiproliferative activity against colorectal and pancreatic cell lines. Of the new species presented in this study, one compound (5-(chloromethyl)-2,2′-bipyridine derivative) shows significant inhibition of pancreatic tumour growth in vivo in zebrafish-Panc-1 xenografts. The complex is noticeably effective at 8 μM concentration, lower than its in vitro IC50 values, being also capable of inhibiting in vivo cancer cells dissemination.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/330406</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/330406/files/d2dt04041g.pdf</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/330406/files/d2dt04041g1.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1039/D2DT04041G</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/issn/1477-9226</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/issn/1477-9234</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY-NC</dc:rights>
  <dc:source>Dalton Transactions. - London, UK: Royal Society of Chemistry (RSC). - 2023, vol. 52, no. 20, p. 6934-6944</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">rhenium</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">tricarbonyl</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">anticancer</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/54</dc:subject>
  <dc:title xmlns:ns4="xml" ns4:lang="en">Synthesis, characterization, and &lt;i&gt;in vivo&lt;/i&gt; evaluation of the anticancer activity of a series of 5- and 6-(halomethyl)-2,2′-bipyridine rhenium tricarbonyl complexes</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
